| |
A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer.
|
|
Today’s Big NewsDec 7, 2023 |
| By Annalee Armstrong AbbVie’s $8.7 billion acquisition of Cerevel will help fill in gaps in the Chicago pharma’s pipeline with new areas to explore in neuroscience, but will regulators play ball? |
|
|
|
By Fraiser Kansteiner While so-called “march-in” rights have yet to materialize in the United States, the controversial measure to cut drug prices appears to be gaining traction with the government. |
By Conor Hale Theranos had a lot of bad ideas, but making blood draws smaller and easier wasn’t necessarily one of them. |
By Angus Liu In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little with Johnson & Johnson. |
|
Thursday, December 13, 2023 | 11am ET / 8am PT In this webinar discover how CDMOs drive efficiency, ensure quality, and enable scalability in biologics production and stay ahead in the dynamic world of biologics with a focus on the transformative CDMO impact. Reigster now.
|
|
By Gabrielle Masson By the end of the year, biopharmas are projected to have raised about $24 billion across about 840 transactions—the lowest tally in four years, according to a new PitchBook analysis. |
By Andrea Park About half a year after announcing its intent to acquire a South Korean maker of tubeless insulin pump technology, Medtronic is scrapping the deal. |
By Fraiser Kansteiner In recent months, Novartis has faced scrutiny from the FDA over Kymriah production shortfalls, a newly posted letter shows. The company says it's working to address the situation. |
By Eric Sagonowsky Responses to Regeneron's bispecific linvoseltamab have risen but so have adverse events and deaths associated with the multiple myeloma drug. |
By Conor Hale Developed by Mosie Baby, the $130 kit contains two pairs of collection cups and specially designed syringes. |
By Angus Liu Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer just as its TIGIT program goes up in flames. |
By Nick Paul Taylor Sanofi has tipped three “pipeline-in-a-product” assets to generate 5 billion euros ($5.4 billion) a year or more. The forecasts are part of a set of predictions intended to justify the drugmaker’s decision to funnel cash into key programs rather than increase its operating profit margin. |
By Andrea Park For the second time in as many weeks, Bayer’s consumer health division has formed a precision health partnership centered on encouraging healthy aging. |
Fierce podcastsDon’t miss an episode |
| | Earlier this year, Fierce Healthcare, Fierce Pharma and Fierce Biotech recognized 50 individuals and companies that are pushing the industry forward. The Fierce 50 winners range from tech innovators to researchers developing novel therapies to providers on the frontlines of changing care. This week on "Podnosis," senior editor Paige Minemyer sat down with staff writers Dave Muoio and Anastassia Gliadkovskaya as well as senior editor Heather Landi to discuss a few of the honorees in more detail. |
|
|---|
|
|
|
Tuesday, December 19, 2023 | 12pm ET / 9am PT Either you want to implement a CLM, or you don’t know how to fix the processes of the one you have in place. Either is a tough place to be in. Join us in this webinar to learn from a CLM solution implementation expert in the highly regulated field of pharmaceuticals. Register now.
|
|
| WhitepaperqPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
| WhitepaperStreamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
| WhitepaperIf you find yourself grappling with bioanalytical challenges during the drug development process, rest assured that these obstacles can be overcome - discover more! Sponsored by: Sannova Analytical |
| Whitepaper High performance computing (HPC) combined with artificial intelligence (AI) and machine learning (ML) can speed up research and development processes and dramatically reduce reliance on expensive clinical trials. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
| Executive SummaryBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| WhitepaperLearn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
| Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
| Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| |
|
